Methods of treatment by administering an anti-BCMA antibody
View Patent ↗A novel receptor in the TNF family is provided: BAFF-R. Chimeric molecules and antibodies to BAFF-R and methods of use thereof are also provided.
1. A method of inhibiting B-cell growth or immunoglobulin production, or both, in a mammal, the method comprising the step of administering to the mammal a therapeutically effective amount of an antibody that specifically binds to a polypeptide consisting of the sequence of SEQ ID NO:1.
2. A method of treating a B-cell lymphoproliferate disorder in a mammal comprising the step of administering to the mammal a therapeutically effective amount of an antibody that specifically binds to a polypeptide consisting of the sequence of SEQ ID NO:1.
3. A method of inhibiting B-cell growth or immunoglobulin production, or both, in a mammal, the method comprising the step of administering to the mammal a therapeutically effective amount of an antibody that specifically binds to a B cell maturation protein (BCMA) polypeptide consisting of a sequence selected from the group consisting of:
a) amino acid residues 1 to 184 of SEQ ID NO:1;
b) amino acid residues 1 to 51 of SEQ ID NO:1; and
c) amino acid residues 8 to 41 of SEQ ID NO: 1.
4. A method of inhibiting B-cell growth or immunoglobulin production, or both, in a mammal, the method comprising the step of administering to the mammal a therapeutically effective amount of an antibody that is immunospecific to an antigenic determinant of a polypeptide consisting of the sequence of SEQ ID NO:1.
5. A method of inhibiting B-cell growth or immunoglobulin production, or both, in a mammal, the method comprising the step of administering to the mammal a therapeutically effective amount of an antibody that specifically binds to a polypeptide consisting of amino acids 1 to 51 of SEQ ID NO:1.
6. A method of inhibiting B-cell growth or immunoglobulin production, or both, in a mammal, the method comprising the step of administering to the mammal a therapeutically effective amount of an antibody that specifically binds to a polypeptide consisting of amino acids 8 to 41 of SEQ ID NO:1.
7. A method of treating systemic lupus erythematosus in a mammal comprising the step of administering to the mammal a therapeutically effective amount of an antibody that specifically binds to a polypeptide consisting of the sequence of SEQ ID NO:1.
8. A method according to any one of claims 1 , 2 , 3 , 4 and 5 – 7 wherein the antibody is a monoclonal antibody.
9. The method of any one of claims 1 , 2 , 3 , 4 and 5 – 7 wherein the mammal is human.
10. The method of any one of claims 1 , 2 , 3 , 4 and 5 – 7 wherein the antibody is recombinantly produced.
11. The method of any one of claims 1 , 2 , 3 , 4 and 5 – 7 wherein the antibody is humanized.
12. The method of any one of claims 1 , 2 , 3 , 4 and 5 – 7 wherein the antibody is chimeric.
13. The method of any one of claims 1 , 2 , 3 , 4 and 5 – 7 wherein the antibody comprises human constant domains.
14. The method of any one of claims 1 , 2 , 3 , 4 and 5 – 7 wherein the antibody comprises a F(ab′)2 fragment.
15. The method of claim 1 , wherein the mammal has an autoimmune disease.
16. The method of claim 1 , wherein the mammal has hypertension.
17. The method of claim 1 , wherein the mammal has a renal disorder.
18. The method of claim 1 , wherein the mammal has inflammation.